Status:
ACTIVE_NOT_RECRUITING
Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery
Lead Sponsor:
Peking University First Hospital
Collaborating Sponsors:
Peking University Cancer Hospital & Institute
The Second Affiliated Hospital of Chongqing Medical University
Conditions:
Pancreatic Cancer
Surgery
Eligibility:
All Genders
45-90 years
Phase:
PHASE4
Brief Summary
Pancreatic cancer remains a devastating disease with an average 5-year survival rate of about 3-5%. Previous retrospective studies showed that perioperative epidural block and/or dexamethasone are ass...
Detailed Description
Pancreatic cancer is the fourth leading cause of cancer-related death in the world, and is estimated to become the second one in 2030. For patients with resectable pancreatic cancer, radical surgery i...
Eligibility Criteria
Inclusion
- Age ≥45 and \<90 years;
- Clinically diagnosed as resectable or possibly resectable pancreatic cancer and scheduled to undergo radical surgery;
- Agreed to receive epidural block and postoperative patient-controlled analgesia;
- Agreed to participate in the study and provided written informed consent.
Exclusion
- Clinical evidence of unresectable pancreatic cancer or plan to undergo biopsy;
- Previous surgery for pancreatic cancer, scheduled to undergo resurgery for recurrence or metastasis;
- Complicated with primary malignant tumor in other organ(s), either previously or at present;
- Complicated with autoimmune diseases, receiving either glucocorticoids or other immunosuppressants before surgery;
- Unable to complete preoperative evaluation due to severe dementia, language barrier, coma, or end-stage diseases;
- Severe hepatic dysfunction (Child-Pugh C), severe renal insufficiency (serum creatinine \>442 µmol/L or requirement of renal replacement therapy), or American Society of Anesthesiologists classification ≥V；
- Contradictions to epidural anesthesia, including spinal malformation, history of spinal surgery, coagulation disorder, suspected infection at the site of puncture, or severe low back pain;
- Other conditions that are considered unsuitable for study participation;
- Refused to participate in the study.
Key Trial Info
Start Date :
September 11 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2026
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT04025840
Start Date
September 11 2019
End Date
November 1 2026
Last Update
July 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034